Infinity-Lock Button System

K180243 · Xiros, Ltd. · HTN · Apr 3, 2018 · Orthopedic

Device Facts

• Record ID: K180243
• Device Name: Infinity-Lock Button System
• Applicant: Xiros, Ltd.
• Product Code: HTN · Orthopedic
• Decision Date: Apr 3, 2018
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 888.3030
• Device Class: Class 2
• Attributes: Therapeutic

Intended Use

The Infinity-Lock™ Button System is intended to provide fixation during the healing process following a syndesmotic trauma, such as fixation of acromioclavicular separations due to coracoclavicular ligament disruption and as an adjunct in external and intramedullary fixation systems involving plates.

Device Story

Infinity-Lock™ Button System provides bone fixation during healing of syndesmotic trauma; specifically acromioclavicular separations. System components include 240 mm Tube-Tape, titanium alloy button, disposable cannulated drill bit, and guidewire. Requires use of coracoid passer (e.g., Xiros CCHook). Device functions via mechanical reduction of clavicle to required position; similar to predicate suture-button fixation systems. Used by surgeons in clinical/OR settings. Output is physical stabilization of bone segments. Benefits include secure fixation during ligament healing process.

Clinical Evidence

Bench testing only. Comparison against AC TightRope™ Repair Kit Titanium (K052776) for ultimate tensile strength (UTS) and fatigue performance (UTS and extension after fatiguing) showed no statistically significant differences. Pyrogenicity testing (LAL Gel Clot method) passed with <20 EU/device.

Technological Characteristics

Implantable system consisting of 240 mm polymeric Tube-Tape and titanium alloy button. Includes disposable cannulated drill bit and guidewire. Mechanical fixation principle. No software or electronic components.

Indications for Use

Indicated for patients with acromioclavicular separations resulting from disruption to the coracoclavicular ligaments.

Regulatory Classification

Identification

Single/multiple component metallic bone fixation appliances and accessories are devices intended to be implanted consisting of one or more metallic components and their metallic fasteners. The devices contain a plate, a nail/plate combination, or a blade/plate combination that are made of alloys, such as cobalt-chromium-molybdenum, stainless steel, and titanium, that are intended to be held in position with fasteners, such as screws and nails, or bolts, nuts, and washers. These devices are used for fixation of fractures of the proximal or distal end of long bones, such as intracapsular, intertrochanteric, intercervical, supracondylar, or condylar fractures of the femur; for fusion of a joint; or for surgical procedures that involve cutting a bone. The devices may be implanted or attached through the skin so that a pulling force (traction) may be applied to the skeletal system.

Predicate Devices

• AC TightRope™ Repair Kit Titanium (K052776)

Reference Devices

• Lockdown™ Acromioclavicular (AC) device (K091207)
• Infinity-Lock 3 (K171680)
• Infinity-Lock 5 (K171680)
• SECURE-LOOP (K151601)

Submission Summary (Full Text)

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image contains two logos. The logo on the left is the Department of Health & Human Services - USA logo. The logo on the right is the FDA U.S. Food & Drug Administration logo. The FDA logo is in blue.

April 3, 2018

Xiros Ltd Stephen Seed Compliance Director Springfield House, Whitehouse Lane Leeds, West Yorkshire LS19 7UE United Kingdom

Re: K180243

Trade/Device Name: Infinity-Lock™ Button System Regulation Number: 21 CFR 888.3030 Regulation Name: Single/multiple component metallic bone fixation appliances and accessories Regulatory Class: Class II Product Code: HTN Dated: January 26, 2018 Received: January 29, 2018

Dear Mr. Seed:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803); good

{1}------------------------------------------------

manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email ([e-mail]) or phone [phone] or 301-796-7100).

Sincerely,

# Mark N. Melkerson -S

Mark N. Melkerson Director Division of Orthopedic Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

Form Approved: OMB No. 0910-0120

Expiration Date: January 31, 2017

See PRA Statement below.

### DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration

# Indications for Use

510(k) Number (if known) K180243

Device Name

Infinity-LockTM Button System

Indications for Use (Describe)

The Infinity-Lock™ Button System is intended to provide fixation during the healing process following a syndesmotic trauma, such as fixation of acromioclavicular separations due to coracoclavicular ligament disruption and as an adjunct in external and intramedullary fixation systems involving plates.

The Infinity-Lock™ Button System is indicated for patients with acromioclavicular separations resulting from disruption to the coracoclavicular ligaments.

Type of Use (Select one or both, as applicable)

> Prescription Use (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

#### CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

#### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and comblete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff [e-mail]

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

Image /page/3/Picture/0 description: The image shows the word "XIROS" in a rounded, gray box. The box has rounded corners and a thick gray outline. A thin gray line extends from the upper right corner of the box, suggesting a connection or continuation to something outside the frame. The text "XIROS" is in a bold, sans-serif font and is centered within the box.

# 510(k) Summary

In accordance with 21 CFR 807.92, the following information constitutes Xiros Ltd. 510(k) summary for the Infinity-Lock™ Button System.

# I. SUBMITTER INFORMATION

| Submitter`s Name: | Xiros Limited |
|-------------------------|--------------------------------------------------------------------------|
| Address: | Springfield House<br>Whitehouse Lane<br>Leeds LS19 7UE<br>United Kingdom |
| Telephone Number: | [phone] |
| Fax Number: | [phone] |
| Contact Person: | Stephen Seed (Compliance Director) |
| Date: | 26 January 2018 |
| 510(k) document number: | K180243 |

# II. DEVICE IDENTIFICATION

| Name of Device: | Infinity-Lock™ Button System |
|-----------------------|------------------------------|
| Trade Name: | Infinity-Lock™ Button System |
| Common or usual name: | Button/suture |
| Classification Name: | Washer, bolt nut |
| Regulatory Class: | Class II |
| Product Code: | HTN |
| Regulation: | 888.3030 |
| Panel: | Orthopedic |

{4}------------------------------------------------

Image /page/4/Picture/0 description: The image shows the word "XIROS" in gray, set against a white background. The word is enclosed in a gray, rounded rectangle. A gray line extends from the right side of the rectangle, curving slightly upwards.

# III. PREDICATE DEVICE

AC TightRope™ Repair Kit Titanium (AR-2257) manufactured by Arthrex Inc, K052776. This predicate has not been subject to a design related recall.

Reference device 1. for fixation at the clavicle for essentially the same indications for use; Lockdown™ Acromioclavicular (AC) device, manufactured by Surgicraft (Trading name of Mandaco 569 Limited), K091207.

Reference device 2. for materials in Tube-Tape within the very general scope of the reference device intended use for soft tissue approximation: Infinity-Lock 3, Infinity-Lock 5, manufactured by Xiros Limited, K171680.

Reference device 3. for materials in Button for different intended purpose: SECURE-LOOP, manufactured by Xiros Limited, K151601.

# IV. DEVICE DESCRIPTION

The Infinity-Lock™ Button System comprises a permanent implantable 240 mm Tube-Tape and titanium alloy Button together with a disposable cannulated drill bit and guidewire. A coracoid passer, such as the Xiros CCHook, is also required.

## V. INDICATIONS FOR USE

The Infinity-Lock™ Button System is intended to provide fixation during the healing process following a syndesmotic trauma, such as fixation of acromioclavicular separations due to coracoclavicular ligament disruption and as an adjunct in external and intramedullary fixation systems involving plates.

The Infinity-Lock™ Button System is indicated for patients with acromioclavicular separations resulting from disruption to the coracoclavicular ligaments.

# VI. COMPARISIONS OF TECHNOLOGICAL CHARACTERISTICS WITH THE PREDICATE DEVICE

The Infinity-Lock™ Button System has the same technological characteristics as the predicate device, with respect to intended use (the subject device falls within the scope of the predicate device), labelling, anatomical site, similar basic design consisting of titanium buttons and polymeric sutures and a similar surgical technique using mechanical means to reduce the clavicle to the required position.

{5}------------------------------------------------

Image /page/5/Picture/0 description: The image contains a gray rounded rectangle with the word "XIROS" in bold, gray letters inside. The rectangle has a small extension at the top, giving it a slightly stylized appearance. The background is plain and white.

# VII. PERFORMANCE DATA

The Infinity-Lock™ Button System when tested against the AC TightRope™ Repair Kit Titanium (K052776) for Ultimate tensile strength (UTS), UTS after fatiguing and extension affer fatiguing, was not statistically significantly different and determined to be substantially equivalent. Pyrogenicity testing was carried out using LAL testing via the Gel Clot method and a pass result of <20 EU/device obtained. The testing demonstrated that the differences between the new device and the predicate device do not raise any new issues of safety and efficacy. The performance data benefit/risk analysis concluded that the differences encountered do not affect the safety and efficacy of the new device in relation to the predicate.

Summary: Based on the pre-clinical testing performance, the Infinity-Lock™ Button System is found to have a safety and effectiveness profile that is similar to the predicate device.

## VIII. CONCLUSION

Testing performed demonstrate that the Infinity-Lock™ Button System is substantially equivalent to the AC TightRope™ Repair Kit Titanium.

Xiros therefore conclude the Infinity-Lock™ Button System is substantially equivalent to the AC TightRope™ Repair Kit Titanium manufactured by Arthrex Inc.